When the inspection reveals that the manufacture or repackaging and relabelling carried out in the context of the distribution of a raw material for pharmaceutical use does not comply with the good practices provided for in Article L. 5138-3, the inspected establishment shall immediately inform the manufacturers of the medicinal products in which this raw material is used.
If a certificate has previously been issued to this establishment, the Director General of the Agence nationale de sécurité du médicament et des produits de santé shall terminate its validity. Copies of this certificate held by the holder are immediately returned to the Agency.